Evidence map›Paper›PMID 30531622›Full record

ArticlePlastic and reconstructive surgery2019

Analysis of Keloid Response to 5-Fluorouracil Treatment and Long-Term Prevention of Keloid Recurrence.

Ryan LaRanger, Anis Karimpour-Fard, Christopher Costa, David Mathes, Woodring E Wright, Tae Chong

Open access · greenAbstract read
In one paragraph

Article in Plastic and reconstructive surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. [Research advances in the treatment of keloid with glucocorticoids].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023
    Review
  5. Diagnosis and Treatment of Keloid: Method Summary and Effect Evaluation.Clinical, cosmetic and investigational dermatology · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Paradigms in Complex Facial Scar Management.Seminars in plastic surgery · 2020
    Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ryan LaRangerFrom the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.
Anis Karimpour-FardFrom the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.
Christopher CostaFrom the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.
David MathesFrom the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.
Woodring E WrightFrom the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.
Tae ChongFrom the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.
The University of Texas Southwestern Medical Center · US

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
Technology Development for a MolBio Knowledge-BaseR01LM008111 · NLM · UNIVERSITY OF COLORADO DENVER · PI HUNTER, LAWRENCE E · 2004 to 2021
$9.7M
Bio Text NLPR01LM009254 · NLM · UNIVERSITY OF COLORADO DENVER · PI HUNTER, LAWRENCE E · 2006 to 2018
$5.9M
UT Southwestern Center for Translational Medicine (UL18Kl2/TL1)TL1TR001104 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$418k
NCATS NIH HHS TL1 TR001104NCATS NIH HHS UL1 TR001105NLM NIH HHS R01 LM008111NLM NIH HHS R01 LM009254
6 · The paper itself

Abstract

Keloids are benign fibroproliferative skin tumors that can cause disfigurement and disability. Although they frequently recur after excision or medical management and can affect 6 to 16 percent of African Americans, there is no gold standard therapy. Keloids are challenging to study because there are no animal or in vitro models of this disorder. This makes it very difficult to validate data from treated tissue samples or cells and develop targeted therapies for this disease. In this study, the authors demonstrate that intralesional 5-fluorouracil injection after keloid excision prevents recurrence for 2 years, with no reported adverse events. The authors analyze the expression of treated and untreated biopsy specimens of the same keloids in their native context to capture insights that may be missed by in vitro cell culture models and correct for intrakeloid variability. Random forest analysis of the microarray data dramatically increased the statistical power of the authors' results, permitting hypothesis-free creation of a gene expression profile of 5-fluorouracil-treated keloids. Through this analysis, the authors found a set of genes, including YAP1 and CCL-2, whose expression changes predict 5-fluorouracil therapy status and include genes that have not previously been associated with keloid biology and are of unknown function. The authors further describe keloid heterogeneity for the first time using multidimensional analysis of their microarray results. The methods and tools the authors developed in this research may overcome some of the challenges in studying keloids and developing effective treatments for this disease. CLINICAL QUESTION/LEVEL OF EVIDENCE:: Therapeutic, V.

Indexed as

Adaptor Proteins, Signal TransducingBiopsyChemokine CCL2DermisFluorouracilFollow-Up StudiesGene Expression ProfilingHumansInjections, IntralesionalKeloidPhosphoproteinsRecurrenceTranscription FactorsTreatment OutcomeYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingCCL2 protein, humanChemokine CCL2FluorouracilPhosphoproteinsTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID30531622
PMCPMC6349497
OpenAlexW2905097725

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.